Company

BioLight Life Sciences Ltd

Headquarters: Tel Aviv, Israel

Employees: 5

TASE: BOLT -0.84%

Market Cap

₪23.9 Million

ILS as of Jan. 1, 2024

US$6.6 Million

Market Cap History

BioLight Life Sciences Ltd market capitalization over time

Evolution of BioLight Life Sciences Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of BioLight Life Sciences Ltd

Detailed Description

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. The company's ophthalmic product offering and pipeline of product candidates include IOPtiMate, a laser-based surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for dry eye syndrome; Eye-D, a controlled release drug-delivery insert platform; OphRx, a non-invasive topical drug delivery technology; and LipiTear, a micro-emulsion technology for the dry eye treatment, as well as for the treatment of other ocular diseases. It also invests in cancer diagnostics technologies, including proprietary tests that are designated for bladder, cervical, multiple myeloma, and other cancers. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

BioLight Life Sciences Ltd has the following listings and related stock indices.


Stock: TASE: BOLT wb_incandescent

Details

Headquarters:

Atidim Park Tel Aviv

2nd Floor Building 7 Entrance 1

Tel Aviv, 6158101

Israel

Phone: 972 7 327 53400

Fax: 972 7 327 53401